第六章 結論與建議
第二節、 建議
本研究係癌症用藥之經濟評估研究，對於後續研究有部分建議，詳細內容如 下所列：
本研究利用全民健康保險資料庫進行晚期非小細胞肺癌病患定義，後續研究 可針對如何利用 ICD-9-CM、藥物及檢驗檢查進行更精確之定義，發展除癌症登記 檔案外，使用全民健康保險資料庫進行肺癌相關研究之途徑。
在模擬分析方面，本研究利用加速失敗時間模式進行存活函數之模擬，係因假 定時間與風險並無比例關係，後續研究亦可針對疾病惡化、存活甚至罹病機率進行 更為詳細之探討，提供更充分之證據讓研究者進行方法學之選擇，雖本研究利用 AIC 及 BIC 值進行模式配適之指標判定，若後續研究能進行更為深入之討論，定 能利用更精細之角度，判定母數分配與存活函數間之關係；成本效用分析面可針對 各用藥策略進行不良反應之細緻探討，將臺灣地區晚期非小細胞肺癌病患使用標 準化學治療藥物之不良反應發生率進行討論，將不良反應之間接成本納入多維敏 感度分析之變項進行更周延詳實之討論，建構更為完整之成本效用分析模式。
最後，臺灣地區對於非小細胞肺癌病患之生活品質討論甚為缺乏，進行經濟評 估之研究時，往往僅能利用國外已成熟之生活品質研究進行推論，若後續研究能將 此文獻缺口充實，定能提升癌症用藥之經濟評估方法之證據力量，為政策分析及決 策提供更佳之證據。
97
參考文獻
中文文獻
台 灣 癌 症 登 記 中 心 ， 2013 。 癌 症 五 年 相 對 存 活 率 統 計 。 引 自 ： http://tcr.cph.ntu.edu.tw/uploadimages/Survival_97_101.pdf
施穎銘、陳育民，2008。非小細胞肺癌的標靶治療。[Targeted Therapy in Non-small Cell Lung Cancer]。內科學誌，19（1），8-13。
徐偉勳、李日翔、林家齊、楊志新，2014。肺癌嶄新標靶治療研究現況。台灣醫學，
18（6），688-694。
廖唯昱、施金元、余忠仁，2014。ALK (anaplastic lymphoma kinase)抑制劑在有 ALK 融合蛋白表現肺癌病人的治療。台灣醫學，18（6），661-666。
臺灣癌症臨床研究合作組織，2014。肺癌臨床指引。國家衛生研究院。
衛生福利部中央健康保險署，2015。2014 年國人全民健康保險就醫疾病資訊。
衛 生 福 利 部 國 民 健 康 署 ， 2015 。 中 華 民 國 101 年 癌 症 登 記 年 報 。 引 自 ： http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?
No=201504290001
賴美淑，2002。以健保申報醫療利用資料，建立台灣糖尿病人世代追蹤實證研究計 畫第一年（三年計畫）。
外文文獻
Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, & Wordsworth, S. (2010).
Applied Methods of Cost-effectiveness Analysis in Healthcare.
Atherly, A. J., & Camidge, D. R. (2012). The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer, 106(6), 1100-1106. doi:
10.1038/bjc.2012.60
Awad, M. M., & Shaw, A. T. (2014). ALK Inhibitors in Non–Small Cell Lung Cancer Crizotinib and beyond. Clin Adv Hematol Oncol, 12(7), 429-439.
Azzoli, C. G., Baker, S., Jr., Temin, S., Pao, W., Aliff, T., Brahmer, J., Giaccone, G. (2009).
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27(36), 6251-6266. doi: 10.1200/jco.2009.23.5622
Bender, R., Augustin, T., & Blettner, M. (2005). Generating survival times to simulate Cox proportional hazards models. Statistics in Medicine, 24(11), 1713-1723. doi:
10.1002/sim.2059
Cameron, L., & Solomon, B. (2015a). New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Curr Treat Options Oncol, 16(10), 367. doi:
10.1007/s11864-015-0367-z
Cameron, L., & Solomon, B. (2015b). New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Curr Treat Options Oncol, 16(10), 49. doi:
10.1007/s11864-015-0367-z
Cao, Y., Xiao, G., Qiu, X., Ye, S., & Lin, T. (2014). Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. PLoS One, 9(12), e114008. doi: 10.1371/journal.pone.0114008
Carlson, J. J., Reyes, C., Oestreicher, N., Lubeck, D., Ramsey, S. D., & Veenstra, D. L.
(2008). Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer, 61(3), 405-415. doi:
10.1016/j.lungcan.2007.12.023
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer, 8(1), 11-23. doi:
http://www.nature.com/nrc/journal/v8/n1/suppinfo/nrc2291_S1.html
Chou, K. T., Chen, Y. M., Lin, K. C., Tsai, C. M., Lee, Y. C., & Perng, R. P. (2010). Non-Small-Cell Lung Cancer in Patients Older than Eighty Years. 台灣癌症醫誌, 26(1), 3-11.
Cooper, M. R., Chim, H., Chan, H., & Durand, C. (2015). Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Ann Pharmacother, 49(1), 107-112. doi:
10.1177/1060028014553619
Costa, D. B., Shaw, A. T., Ou, S. H., Solomon, B. J., Riely, G. J., Ahn, M. J., Crino, L.
(2015). Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. doi:
10.1200/jco.2014.59.0539
99
Cox, C., Chu, H., Schneider, M. F., & Muñoz, A. (2007). Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Statistics in Medicine, 26(23), 4352-4374. doi: 10.1002/sim.2836
Devlin, N., & Parkin, D. (2004). Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ, 13(5), 437-452. doi: 10.1002/hec.864
Deyo, R. A., Cherkin, D. C., & Ciol, M. A. (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol, 45(6), 613-619.
Djalalov, S., Beca, J., Hoch, J. S., Krahn, M., Tsao, M. S., Cutz, J. C., & Leighl, N. B.
(2014). Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol, 32(10), 1012-1019. doi: 10.1200/JCO.2013.53.1186
Evans, D. B., Lim, S. S., Adam, T., & Edejer, T. T. (2005). Evaluation of current strategies and future priorities for improving health in developing countries. Bmj, 331(7530), 1457-1461. doi: 10.1136/bmj.38658.675243.94
Fu, S., Wang, H. Y., Wang, F., Huang, M. Y., Deng, L., Zhang, X., Shao, J. Y. (2015).
Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. Chin J Cancer, 34(9), 404-412. doi: 10.1186/s40880-015-0032-8 Gainor, J. F., Tan, D. S., De Pas, T., Solomon, B. J., Ahmad, A., Lazzari, C., Shaw, A. T.
(2015). Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res. doi:
10.1158/1078-0432.ccr-14-3009
Gautschi, O., Schefer, H., Riklin, C., Strobel, K., & Diebold, J. (2013). Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer. Onkologie, 36(6), 342-347. doi: 10.1159/000351163 Gerdtham, U.-G., & Zethraeus, N. (2003). PREDICTING SURVIVAL IN
COST-EFFECTIVENESS ANALYSES BASED ON CLINICAL TRIALS. International Journal of Technology Assessment in Health Care, 19(03), 507-512. doi:
doi:10.1017/S0266462303000436
Girard, N., Audigier-Valette, C., Cortot, A. B., Mennecier, B., Debieuvre, D., Planchard, D., Barlesi, F. (2015). ALK-rearranged non-small cell lung cancers: how best to
optimize the safety of crizotinib in clinical practice? Expert Rev Anticancer Ther, 15(2), 225-233. doi: 10.1586/14737140.2014.986103
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Sobin, L. (2007). The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology, 2(8), 706-714. doi: http://dx.doi.org/10.1097/JTO.0b013e31812f3c1a
Gregory A. Masters, Sarah Temin, Christopher G. Azzoli, Giuseppe Giaccone, Sherman Baker Jr, Julie R. Brahmer, . . . Johnson, D. H. (2015). Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 33(30), 3488-3515. doi:
10.1200/JCO.2015.62.1342
Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N., Heymach, J. V., Perrone, F., De Marinis, F. (2008). Second-line treatment of advanced non-small cell lung cancer.
J Thorac Oncol, 3(4), 430-440. doi: 10.1097/JTO.0b013e318168c815
Gridelli, C., de Marinis, F., Cappuzzo, F., Di Maio, M., Hirsch, F. R., Mok, T., Ciardiello, F. (2014). Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer, 15(3), 173-181. doi: 10.1016/j.cllc.2013.12.002 Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical
Medicine (2014). Lung cancer survival statistics. Available
Group, N.-s. C. L. C. C. (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. . Bmj, 311(7010), 899-909.
Guo, Y., Ma, J., Lyu, X., Liu, H., Wei, B., Zhao, J. (2014). Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. BMC Cancer, 14, 834. doi: 10.1186/1471-2407-14-834
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008). Lung cancer. N Engl J Med, 359(13), 1367-1380. doi: 10.1056/NEJMra0802714
Hsu, K.-H., Ho, C.-C., Hsia, T.-C., Tseng, J.-S., Su, K.-Y., Wu, M.-F., Chang, G.-C.
(2015). Identification of Five Driver Gene Mutations in Patients with
Treatment-101
Naïve Lung Adenocarcinoma in Taiwan. PLoS One, 10(3), e0120852. doi:
10.1371/journal.pone.0120852
Hsu, S. C., Hung, T. H., Wang, C. W., Ng, K. F., & Chen, T. C. (2015). Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer. Pathol Int, 65(5), 231-239. doi:
10.1111/pin.12268
Jett, J. R., Schild, S. E., Keith, R. L., & Kesler, K. A. (2007). Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 266s-276s. doi: 10.1378/chest.07-1380
Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., . . . Pazdur, R.
(2015). FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. doi:
10.1158/1078-0432.ccr-14-3157
Kim, H. R., Shim, H. S., Chung, J. H., Lee, Y. J., Hong, Y. K., Rha, S. Y., Cho, B. C.
(2012). Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Cancer, 118(3), 729-739. doi: 10.1002/cncr.26311
Kim, S., Kim, T. M., Kim, D.-W., Go, H., Keam, B., Lee, S.-H., Heo, D. S. (2013).
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. Journal of Thoracic Oncology, 8(4), 415-422. doi: http://dx.doi.org/10.1097/JTO.0b013e318283dcc0
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Janne, P. A. (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res, 14(13), 4275-4283. doi: 10.1158/1078-0432.ccr-08-0168
Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Iafrate, A. J. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
N Engl J Med, 363(18), 1693-1703. doi: 10.1056/NEJMoa1006448
Lange, A., Prenzler, A., Frank, M., Golpon, H., Welte, T., & von der Schulenburg, J. M.
(2014). A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med, 14, 192. doi:
10.1186/1471-2466-14-192
Lemjabbar-Alaoui, H., Hassan, O., Yang, Y. W., & Buchanan, P. (2015). Lung cancer:
Biology and treatment options. Biochim Biophys Acta. doi:
10.1016/j.bbcan.2015.08.002
Liao, B. C., Shao, Y. Y., Chen, H. M., Shau, W. Y., Lin, Z. Z., Kuo, R. N., Lai, M. S.
(2015). Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer, 16(2), 137-143. doi: 10.1016/j.cllc.2014.09.004
Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G., & Rosen, S. (2015). Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ, 93(2), 118-124. doi: 10.2471/blt.14.138206
McCabe, C., Claxton, K., & Culyer, A. J. (2008). The NICE cost-effectiveness threshold:
what it is and what that means. Pharmacoeconomics, 26(9), 733-744.
Michael F. Drummond, Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, &
Stoddart, G. L. (2005). Methods for the Economic Evaluation of Health Care Programmes (3rd edition).
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Fukuoka, M.
(2010). Gefi tinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. lancet, 11, 121-128. doi:
10.1016/s14702045(09)70364-x
Mok, T., Kim, D.-W., Wu, Y.-L., Solomon, B. J., Nakagawa, K., Mekhail, T., Blackhall, F. H. (2014). First-line crizotinib versus cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol (Meeting Abstracts), 32(15_suppl), 8002-.
Morodomi, Y., Takenoyama, M., Inamasu, E., Toyozawa, R., Kojo, M., Toyokawa, G., Ichinose, Y. (2014). Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy. Anticancer Res, 34(7), 3825-3830.
National Institute for Health and Care Excellence (2012). Methods for the development of NICE public health guidance (third edition).
National Institute for Health and Care Excellence (2013). NICE consults on new draft recommendations for lung cancer drug.
103
National Institute for Health and Care Excellence(2013). Guide to the methods of technology appraisal 2013.
Network, N. C. C. (2015). Non-Small Cell Lung Cancer. NCCN Guidelines for Patients.
Niu, F.-Y., & Wu, Y.-L. (2015). Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Onco Targets and Therapy, 8, 999-1007. doi: 10.2147/OTT.S64664
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker, S., Jr., Somerfield, M. R. (2004). American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol, 22(2), 330-353. doi: 10.1200/jco.2004.09.053
Ranson, M., Davidson, N., Nicolson, M., Falk, S., Carmichael, J., Lopez, P., Thatcher, N.
(2000). Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 92(13), 1074-1080.
Richly, H., Kim, T. M., Schuler, M., Kim, D. W., Harrison, S. J., Shaw, A. T., Solomon, B. (2015). Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood, 126(10), 1257-1258. doi:
10.1182/blood-2014-12-617779
Ridge, C. A., McErlean, A. M., & Ginsberg, M. S. (2013). Epidemiology of lung cancer.
Semin Intervent Radiol, 30(2), 93-98. doi: 10.1055/s-0033-1342949
Robinson, L. A., Ruckdeschel, J. C., Wagner, H., Jr., & Stevens, C. W. (2007). Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 243s-265s. doi: 10.1378/chest.07-1379
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Paz-Ares, L. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13(3), 239-246. doi: 10.1016/s1470-2045(11)70393-x
Roszkowski, K., Pluzanska, A., Krzakowski, M., Smith, A. P., Saigi, E., Aasebo, U., Berille, J. (2000). A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients
with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
Lung Cancer, 27(3), 145-157.
Rothschild, S. I., & Gautschi, O. (2013). Crizotinib in the treatment of non--small-cell lung cancer. Clin Lung Cancer, 14(5), 473-480. doi: 10.1016/j.cllc.2013.04.006 Royston, P. (2001). The Lognormal Distribution as a Model for Survival Time in Cancer,
With an Emphasis on Prognostic Factors. Statistica Neerlandica, 55(1), 89-104.
doi: 10.1111/1467-9574.00158
Sahu, A., Prabhash, K., Noronha, V., Joshi, A., & Desai, S. (2013). Crizotinib: A comprehensive review. South Asian J Cancer, 2(2), 91-97. doi: 10.4103/2278-330x.110506
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Johnson, D. H. (2002). Comparison of Four Chemotherapy Regimens for Advanced Non–
Small-Cell Lung Cancer. New England Journal of Medicine, 346(2), 92-98. doi:
doi:10.1056/NEJMoa011954
Scott, W. J., Howington, J., Feigenberg, S., Movsas, B., & Pisters, K. (2007). Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 234s-242s. doi:
10.1378/chest.07-1378
Sculier, J. P., Berghmans, T., & Meert, A. P. (2015). Advances in target therapy in lung cancer. Eur Respir Rev, 24(135), 23-29. doi: 10.1183/09059180.00011014
Shah, Koonal K., Tsuchiya, Aki, Wailoo, Allan J. (2014). Valuing health at the end of life:
an empirical study of public preferences. The European Journal of Health Economics, 15(4), 389-399.
Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crino, L., Ahn, M. J., Janne, P. A.
(2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med, 368(25), 2385-2394. doi: 10.1056/NEJMoa1214886
Shi, Y., & Sun, Y. (2015). Medical management of lung cancer: Experience in China.
Thorac Cancer, 6(1), 10-16. doi: 10.1111/1759-7714.12168
Shiono, S., Katahira, M., Abiko, M., & Sato, T. (2015). Smoking is a perioperative risk factor and prognostic factor for lung cancer surgery. Gen Thorac Cardiovasc Surg, 63(2), 93-98. doi: 10.1007/s11748-014-0461-3
105
American Cancer Society (2015a). Cancer Facts & Figure 2015. Available from http://www.cancer.org/acs/groups/content/@editorial/documents/document/acsp c-044552.pdf
American Cancer Society (2015b). Lung Cancer (Non-Small Cell). Available from http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf Socinski, M. A., Crowell, R., Hensing, T. E., Langer, C. J., Lilenbaum, R., Sandler, A. B.,
& Morris, D. (2007). Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 277s-289s. doi: 10.1378/chest.07-1381
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Mano, H.
(2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561-566. doi: 10.1038/nature05945
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Blackhall, F. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 371(23), 2167-2177. doi:
doi:10.1056/NEJMoa1408440
Spiro, S. G., Rudd, R. M., Souhami, R. L., Brown, J., Fairlamb, D. J., Gower, N. H., West, P. (2004). Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax, 59(10), 828-836. doi: 10.1136/thx.2003.020164
Stewart, B. W., Wild, C. P. (2014). World Cancer Report 2014. Available from http://www.who.int/mediacentre/factsheets/fs297/en/
Swindell, W. R. (2009). ACCELERATED FAILURE TIME MODELS PROVIDE A USEFUL STATISTICAL FRAMEWORK FOR AGING RESEARCH.
Experimental gerontology, 44(3), 190-200. doi: 10.1016/j.exger.2008.10.005 Sy, J. P., & Taylor, J. M. G. (2000). Estimation in a Cox Proportional Hazards Cure Model.
Biometrics, 56(1), 227-236. doi: 10.1111/j.0006-341X.2000.00227.x
Takahashi, T., Sonobe, M., Kobayashi, M., Yoshizawa, A., Menju, T., Nakayama, E., Date, H. (2010). Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol, 17(3), 889-897. doi: 10.1245/s10434-009-0808-7
Timm, A., & Kolesar, J. M. (2013). Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm, 70(11), 943-947. doi: 10.2146/ajhp120261
Trowman, R., Chung, H., Longson, C., Littlejohns, P., Clark, P.(2011). The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. Clin Cancer Res, 17(15), 4930-5.
Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., & Lu, Q. (2013). A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One, 8(3), e55917. doi: 10.1371/journal.pone.0055917
Wang, Y., Wang, S., Xu, S., Qu, J., & Liu, B. (2014). Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene:
a meta-analysis. PLoS One, 9(10), e110617. doi: 10.1371/journal.pone.0110617 Warth, A., Muley, T., Meister, M., Stenzinger, A., Thomas, M., Schirmacher, P., Weichert,
W. (2012). The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol, 30(13), 1438-1446. doi: 10.1200/jco.2011.37.2185
Weiss, J. M., & Stinchcombe, T. E. (2013). Second-Line Therapy for Advanced NSCLC.
Oncologist, 18(8), 947-953. doi: 10.1634/theoncologist.2013-0096
Wong, D. W., Leung, E. L., So, K. K., Tam, I. Y., Sihoe, A. D., Cheng, L. C., Pik Wong, M. (2009). The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 115(8), 1723-1733. doi: 10.1002/cncr.24181
World Health Organization, W. (2002). The world health report 2002: reducing risks, promoting healthy life.
World Health Organization, W. (2014). Cost effectiveness and strategic planning (WHO-CHOICE).
Wu, S.-G., Kuo, Y.-W., Chang, Y.-L., Shih, J.-Y., Chen, Y.-H., Tsai, M.-F., Yang, P.-C.
(2012). EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. Journal of Thoracic Oncology, 7(1), 98-104. doi: http://dx.doi.org/10.1097/JTO.0b013e3182370e30
Wu, Y. C., Chang, I. C., Wang, C. L., Chen, T. D., Chen, Y. T., Liu, H. P., Huang, S. F.
(2013). Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One, 8(8), e70839. doi: 10.1371/journal.pone.0070839
107
Yang, P., Kulig, K., Boland, J. M., Erickson-Johnson, M. R., Oliveira, A. M., Wampfler, J., . . . Yi, E. S. (2012). Worse disease-free survival in never-smokers with ALK+
lung adenocarcinoma. J Thorac Oncol, 7(1), 90-97. doi:
10.1097/JTO.0b013e31823c5c32
Zhang, L., Ma, S., Song, X., Han, B., Cheng, Y., Huang, C., Wang, M. (2012). Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. The Lancet Oncology, 13(5), 466-475. doi:
http://dx.doi.org/10.1016/S1470-2045(12)70117-1
http://dx.doi.org/10.1016/S1470-2045(12)70117-1